17 June 2025 - Aldeyra Therapeutics today announced the resubmission of a new drug application to the US FDA for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. 

Per FDA agreement, the only new clinical data included in the resubmitted new drug application were from the recently completed dry eye chamber trial, which achieved the primary outcome.

Read Aldeyra Therapeutics press release